Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

Benzinga · 1d ago
Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.